Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

ABSTRACT: Background: Tofacitinib and other new treatments approved for use in psoriatic arthritis have only recently been included in psoriatic arthritis treatment guidelines, and studies evaluating the relative efficacy of available therapies are important to inform treatment decisions by healthc...

Full description

Bibliographic Details
Main Authors: Dafna D. Gladman, MD, Ana-Maria Orbai, MD, Juan Gomez-Reino, MD, Stacey Chang-Douglass, PhD, Emanuele Leoncini, PhD, Hannah E. Burton, MSc, Keith S. Kanik, MD, Ana Belen Romero, MD, Joseph C. Cappelleri, PhD, Ming-Ann Hsu, MPH
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Current Therapeutic Research
Subjects:
Biologic disease-modifying antirheumatic drug
Network meta-analysis
Psoriatic arthritis
TNFi-IR
TNFi-naïve
Tofacitinib
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X20300278

Internet

http://www.sciencedirect.com/science/article/pii/S0011393X20300278

Similar Items